This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
GSK has entered a strategic partnership with Wave LifeSciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics.
The Abu Dhabi Department of Health (DoH) in the UAE has made a declaration of collaboration with Mass General Brigham’s (MGB) International Center for Genetic Disease (iCGD) to advance lifesciences.
Forge Biologics has joined the public-private collaboration, the Bespoke Gene Therapy Consortium (BGTC), to expedite the development and manufacture of new AAV [adeno-associated virus] gene therapies to treat patients with rare diseases. Shilling was appointed to represent the company on the steering committee of the BGTC.
Forge Biologics and global lifesciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. This will improve accessibility to services for AAV-mediated gene therapy programmes.
CAH is a group of rare genetic disorders affecting the adrenal glands, which produce essential hormones like cortisol, aldosterone and androgens. While manageable, the condition requires lifelong treatment and monitoring to prevent complications and ensure healthy development.
Alkeus Pharmaceuticals has raised $150m in Series B financing to support the registration and launch of gildeuretinol (ALK-001) to treat Stargardt disease, a genetic cause of blindness in children and young adults. The genetic cause is well characterised, but to date there is no effective treatment.
As we step into 2024, the lifesciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables.
Lifescience podcasts have emerged as an invaluable tool for building connections with audiences in the digital era. Furthermore, we’ll explore the unique advertising opportunities that this platform offers, positioning brands at the forefront of the lifescience industry. The result?
Xtalks is proud to announce the launch of the Xtalks LifeScience podcast. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode. Fresh Conversations About LifeScience Topics. She focuses on news relating to the food industry and writes blogs on recruitment and HR in the lifesciences.
On International Women’s Day, Xtalks is celebrating women’s leadership in the lifesciences by highlighting some of the female leaders at the forefront of scientific discovery, as well as the continuing challenges of attaining more equitable representation.
Lifescience workers are one of the most common areas of work that could not eliminate all visits to the office or lab during the COVID-19 pandemic. Additionally, these lifescience companies are now trying to find the new normal for many of their employees to accommodate the new lifestyle they have embraced.
We are proud to have developed Jesduvroq as a new oral treatment where there is a patient desire for more options.” Last December, GSK and Wave LifeSciences entered a strategic partnership to drive the discovery and development of oligonucleotide therapies for new genetic targets.
This month, we highlight new appointments from Lumeris, Lineage Cell Therapeutics, 1910 Genetics, and ADC Therapeutics. . ” Patrick Genestin, 1910 Genetics . “I am excited to join 1910 Genetics at such a pivotal time for the company,” Genestin said. Ben Grabski, Lumeris.
BridgeBio has been highly active in the genetic diseases space. Its investigational therapy infigratinib recently received Breakthrough Therapy designation, becoming the first-ever potential treatment for achondroplasia — a genetic condition affecting bone growth — to achieve this milestone.
If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the lifesciences. The development and widespread adoption of new technologies is key to revolutionizing the way we diagnose, prevent, treat and manage disease. They can be developed and adapted quickly.
One of the more intriguing developments in cancer research in recent years is the growing understanding of clonal hematopoiesis, a phenomenon where blood cells expand from a single clone due to genetic mutations. Clonal hematopoiesis increases in prevalence with age and can precede hematologic malignancies.
Venture capitalists have poured $42 billion into drug development over the past three years. Most small biotech companies rely on venture capitalist funding to develop new drugs but is that a good way to go? billion, which was much lower than previous studies, which have placed the average cost of drug development as $2.8
CF is a progressive genetic disease caused by defective CFTR proteins, which are crucial for regulating salt and water movement in cells. As a result, the diversity of CFTR mutations presents significant challenges in developing therapies that can benefit all CF patients.
GSK and genetic medicines company, Wave LifeSciences, have announced a strategic collaboration to advance oligonucleotide therapeutics across multiple disease areas.
Gene therapies are an attractive way of targeting the underlying genetic mutations, but traditional approaches cannot be used while targeting mutations for Dravet Syndrome, forcing researchers to develop new ways. To tackle this, companies have developed different ways to focus on the gene.
Current Share Price: The announcement follows a $115 million Series D financing in December 2024, co-led by Frazier LifeSciences and Deep Track Capital, with participation from Janus Henderson Investors and Logos Capital. MZE829 aims to mimic a protective genetic variant of APOL1. for an upfront payment of $150 million.
Elevidys is the first FDA-approved gene therapy for DMD a rare genetic disorder characterized by progressive muscle degeneration. Elevidys aims to address the underlying genetic cause by introducing a functional version of the dystrophin gene, which is essential for muscle function. Sarepta is reviewing all available data.
The two studies were recently published online in the journal Science, both of which were led by Jean-Laurent Casanova, an infectious disease geneticist at Rockefeller University. Casanova’s lab is now searching for the genetic driver behind the autoantibodies. Autoimmune Attack and COVID-19 Symptom Severity.
The editorial team also discussed a new rapid molecular test developed by UK-based Genedrive PLC that can help physicians select the best antibiotic to treat babies with to prevent hearing loss. Genedrive’s Genetic Test Can Prevent Hearing Loss in Babies Through Personalized Treatment.
According to GlobalData, there are 60+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of transcription factors for AAV. Encoded Therapeutics develops gene therapies for the treatment of severe genetic disorders.
Duvyzat, a histone deacetylase (HDAC) inhibitor that works to reduce inflammation and muscle loss, is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. According to the FDA, life expectancy for those with DMD has increased over the years, with some patients surviving beyond 30 years.
Studies also indicate that Gen-Xers and Millennials face a significantly higher risk of developing pancreatic and other cancers compared to previous generations. Key factors include: Family h istory: Having close relatives with pancreatic cancer or certain genetic mutations increases risk. percent compared to 18.6
In the lifesciences industry, where company names derived from “biology” or “genetics” are a dime a dozen, it helps to have a brand that stands out. The company is developing treatments for diseases caused by broken mitochondria — the main energy source for human cells.
When lifesciences industry partners with patients and their advocacy communities, the patient voice becomes integrated into the drug development process. However, as with any change, it is gradual, and there is certainly more work to be done in partnership with the patient communities served by these development programs.
Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. Inactive viruses often act as the viral vector, as they’re able to deliver genetic therapies efficiently.
Lawreen is a seasoned biotech and lifescience professional with over 25 years of experience. Lawreen is dedicated to raising awareness about rare diseases like Usher syndrome, supporting and advocating for the USH patient community, and sharing research progress in the hopes of accelerating the development of more treatment options.
can act on existing genetic mutations to trigger inflammation and the development of cancer. Ayesha also talked about how a woman with a unique ability to smell Parkinson’s disease has helped scientists develop a new test that may aid in the early diagnosis of the condition. micrometers (PM2.5)
The new good manufacturing practices facility was established with support from the Singapore Economic Development Board. It comes with quick vaccine fill-finish capabilities and offers end-to-end pharmaceutical development and manufacturing services.
Solid Biosciences has entered a strategic research collaboration with Phlox Therapeutics to expedite the development of new therapies for rare cardiac diseases. Under the research partnership deal, the companies will develop new precision genetic medicines for a severe form of genetic dilated cardiomyopathy (DCM).
Poseida is a clinical-stage biopharmaceutical firm that utilizes its unique non-viral gene engineering methods to develop innovative cell and gene therapies. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode. Scientists working at Poseida Therapeutics.
This initiative is particularly impactful for rare diseases and genetic disorders, where traditional endpoints may be infeasible. Programs like the Rare Disease Endpoint Advancement Pilot encourage collaboration with the FDA to establish novel surrogate endpoints.
The POV highlights the multifaceted nature of health determinants, noting that while genetics play a role, many other factors such as social, economic, and environmental elements are equally important. These determinants are crucial for engaging with digital health tools and services, which can significantly impact health outcomes.
CAMP4’s RNA-based therapies focus on genetic diseases like urea cycle disorders, while Rapport’s small molecules aim to address epilepsy, pain and bipolar disorder. Jupiter joins a wave of biotech IPOs this year, stepping into a competitive space while broadening treatment options for CNS patients.
With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. So, we set out to solve some of the problems,” she explains.
Swiss medical data specialist Sophia Genetics has raised $110 million in an oversubscribed funding round that will be used to boost its headcount and international presence and prepare to take its shares public. The post $110m financing sets up US, Asia expansion for Sophia Genetics appeared first on.
Recruitment and Selection of Participants Obesity affects people across different ages, ethnicities and socioeconomic backgrounds, each with distinct genetic, environmental and behavioral factors contributing to their condition. This diversity requires flexible and inclusive recruitment strategies that can engage a broad participant base.
Current Share Price: PWS is a complex, genetically determined neurodevelopmental disorder that affects multiple organ systems. And hyperphagia is common not only to PWS but also to hypothalamic obesity, binge-eating disorder and certain rare genetic disorders like Bardet-Biedl syndrome.
This therapy, the first of its kind to be administered directly into the brain, addresses a rare genetic disorder that severely affects motor function and dopamine production. Symptoms of AADC deficiency, such as delays in motor skills like sitting, standing and muscle control, often appear in infancy, limiting development.
Experts from Servier and Genuity Science recently spoke on a webinar about using genomics data to drive drug development in heart failure and identify new targets for novel therapeutics. The reverse could also be true whereby the development of coronary artery disease may impact heart rate. HFrEF vs. HFpEF.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content